Thermo Fisher Scientific Inc. $TMO Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 50.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,934 shares of the medical research company’s stock after selling 7,105 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Thermo Fisher Scientific were worth $2,819,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Envestnet Portfolio Solutions Inc. boosted its holdings in Thermo Fisher Scientific by 5.6% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 34,334 shares of the medical research company’s stock valued at $13,921,000 after purchasing an additional 1,816 shares in the last quarter. Concord Wealth Partners boosted its holdings in Thermo Fisher Scientific by 39.5% in the second quarter. Concord Wealth Partners now owns 113 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 32 shares in the last quarter. Vest Financial LLC boosted its holdings in Thermo Fisher Scientific by 39.3% in the second quarter. Vest Financial LLC now owns 4,440 shares of the medical research company’s stock valued at $1,800,000 after purchasing an additional 1,252 shares in the last quarter. MGO One Seven LLC grew its stake in Thermo Fisher Scientific by 26.7% during the 2nd quarter. MGO One Seven LLC now owns 3,204 shares of the medical research company’s stock worth $1,299,000 after buying an additional 676 shares during the last quarter. Finally, Cypress Capital Group purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $479,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO stock opened at $525.08 on Wednesday. The business’s 50 day moving average is $491.00 and its two-hundred day moving average is $448.20. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a market capitalization of $198.28 billion, a P/E ratio of 30.37, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the business posted $5.37 EPS. The company’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on TMO. William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Evercore ISI raised their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $589.10.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last three months. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.